HealthNet MEA to Commercialise COMIDE ER® (Methylphenidate ER) in UAE Under Exclusive Agreement with Anxo Pharmaceutical

The agreement expands HealthNet MEA's specialty pharmaceutical portfolio and supports broader access to extended-release ADHD treatment in the UAE.

DUBAI, DUBAI, UNITED ARAB EMIRATES, September 22, 2026 /EINPresswire.com/ -- HealthNet MEA today announced the signing of an exclusive agreement with Anxo Pharmaceutical Co., Ltd., appointing HealthNet MEA as the exclusive partner responsible for the regulatory registration, commercialisation, marketing and distribution of COMIDE ER® (Methylphenidate Hydrochloride Extended-Release Tablets) in the United Arab Emirates.

> “We are delighted to partner with Anxo Pharmaceutical to bring COMIDE ER® to the UAE, supporting improved access to methylphenidate amid ongoing global supply challenges.”
>
> *Dr Ejike Nwokoro, General Manager, HealthNet MEA*

The partnership represents another significant milestone in HealthNet MEA's strategy of bringing innovative, clinically differentiated pharmaceutical products to the Middle East while improving patient access through strong regulatory, commercial and distribution capabilities.

The agreement comes at an important time for ADHD treatment globally. Healthcare systems across numerous countries have experienced recurring shortages of methylphenidate medicines in recent years, highlighting the importance of strengthening treatment availability and ensuring patients have access to reliable therapeutic options. By introducing COMIDE ER® to the UAE, the partnership aims to broaden treatment choice for healthcare professionals while supporting continuity of care for patients requiring long-acting methylphenidate therapy.

COMIDE ER® utilises OROS® (Osmotic Controlled Release Oral Delivery System) technology, an established extended-release drug delivery platform designed to provide controlled release of methylphenidate from a once-daily tablet. The technology combines an immediate-release outer

layer with a controlled osmotic delivery mechanism that gradually releases the remaining medication throughout the day, supporting consistent drug delivery while reducing the need for multiple daily doses., COMIDE ER® provides healthcare professionals with an additional extended-release treatment option, subject to regulatory approval.



From L to R: Dr. Yan, Lin-Chiuan, General Manager of Anxo and Dr Ejike Nwokoro General Manager of HealthNet MEA.

"We are delighted to partner with Anxo Pharmaceutical to introduce COMIDE ER® to the UAE," said Dr Ejike Nwokoro, General Manager of HealthNet MEA.

"Reliable access to methylphenidate has become an important challenge in many healthcare systems due to recurring global supply constraints. This collaboration reflects our commitment to improving treatment availability while continuing to identify, register and commercialise innovative pharmaceutical products that address genuine healthcare needs across the Middle East. We look forward to working closely with healthcare stakeholders to support the successful introduction of COMIDE ER® following regulatory approval."

“COMIDE ER® is a long-acting medication developed by Anxo for patients with ADHD, which can effectively improve patients' quality of life. We are honoured to collaborate with HealthNet MEA to introduce COMIDE ER® to UAE market. HealthNet MEA has extensive experience in local pharmaceutical distribution and marketing, making an ideal partner for expanding into MEA market. This is also our first collaboration with HealthNet MEA, and we hope that through this strategic alliance, more UAE patients and their families can benefit from this treatment option, while also laying a solid foundation for the company's long-term development in the regional market.” said Dr. Yan, Lin-Chiuan, General Manager of Anxo.

HealthNet MEA will now commence the UAE regulatory submission process for COMIDE ER®. Subject to regulatory approval, HealthNet MEA will implement a comprehensive launch programme encompassing healthcare professional education, scientific engagement, commercial market access initiatives and nationwide distribution to support responsible product introduction and long-term supply continuity.

The agreement also establishes a platform for broader collaboration between HealthNet MEA and Anxo Pharmaceutical as both organisations continue exploring opportunities to introduce

additional innovative pharmaceutical products across the UAE and wider Middle East region.

About HealthNet MEA
HealthNet MEA is a UAE-based, MOHAP/EDE-licensed importer and distributor of medicines, medical devices and specialised healthcare products, providing international manufacturers with a fully integrated pathway into the UAE and wider GCC market. Combining regulatory expertise, GDP-compliant warehousing and agile commercial execution, the company enables faster market access and reliable supply across both hospital and retail channels, positioning itself as a single accountable partner bridging global healthcare innovation with local patient access.

About Anxo Pharmaceutical Co., Ltd
Anxo Pharmaceutical Co., Ltd (hereinafter referred to as Anxo), a professional drug delivery technology developer, is a Taiwanese emerging stock company (TWO:6677). Through its self-developed Drug Delivery System (DDS) platform, Anxo engages in the development, sales, and contract manufacturing of high-tech, difficult generic drugs. To improve patient compliance and convenience, it has now expanded into the 505(b)(2) new drug field, developing drugs for the treatment of schizophrenia through its self-developed NanoCIP (NanoCrystal Injectable (Depot) Platform). Currently, Anxo focusing on the chronic disease market, including cardiovascular diseases, central nervous system diseases, urinary tract diseases, antimicrobial agents, and blood and kidney diseases, and holds over 170 drug licenses (and continuously increasing). Anxo's core advantage lies in its ability to select appropriate technology platforms for product development based on different drug characteristics, and even to improve dosage forms. It currently possesses multiple drug delivery technology platforms, each with its own niche advantages, which are a solid foundation for the company's recent foray into new drug development. For more company information, please visit Anxo’s official website: https://www.anxo.com.tw/.

Media Team
HealthNet MEA
support@healthnetmea.ae

This press release can be viewed online at: https://www.einpresswire.com/article/943981367

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.
© 1995-2026 Newsmatics Inc. All Right Reserved.